At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 16 enrolled
Drug / intervention
Bevacizumab +2 moredrug
Likely dose
Bevacizumab 10 mg/kgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Multicenter Phase II Study of Border Zone Stereotactic Radiosurgery With Bevacizumab in Patients With Recurrent or Progressive Glioblastoma Multiforme
In Brief
A Phase 2 clinical trial evaluating Bevacizumab, Magnetic Resonance Spectroscopy (MRS), and 1 other intervention for Glioblastoma Multiforme and Glioblastoma - Category. Completed, enrolled 16 participants across 1 site.
Detailed Summary
This is a phase II study on the usage of stereotactic Gamma Knife radiosurgery as a boost to the tumor bed border zone in conjunction with the usage of bevacizumab.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsGlioblastoma Multiforme, Glioblastoma - Category
CountriesUnited States
CollaboratorsGenentech, Inc.
Timeline
Phase 2CompletedFinished
2014201520162017201820192020202120222023202420252026
First PostedApr 2014
Enrollment StartMay 2014
Primary CompletionMar 2018
TodayJul 2026
First PostedApr 22, 2014
Enrollment StartMay 1, 2014
Primary CompletionMar 31, 2018
TodayJul 2, 2026
Enrollment to primary: 3.9 yearsPosted 12.2 years ago
Interventions
Bevacizumabdrug
Patients will receive bevacizumab (10 mg/kg) one day before and then at day 14 followed by10 mg/kg/day every 14 days until progression.
Magnetic Resonance Spectroscopy (MRS)procedure
Subjects will have MRS prior to BZ-SRS.
Border Zone Stereotactic Radiosurgery (BZ-SRS)procedure
The 'border zone' of the tumor will be targeted by SRS in a single session.